RESEARCH TRIANGLE PARK, N.C. -- September 16, 2009 – Catalent Pharma Solutions, a leading provider of advanced technologies and outsourced clinical services to the global pharmaceutical and biotechnology industry, will be a Gold Sponsor of the Symposium on Nasal and Pulmonary Drug Delivery on September 17 - 18, 2009 at the Hyatt Regency in Mumbai, India. Due to the vast interest the Indian Pharma Industry has shown in introducing products to regulated markets, such as the United States and Europe, this edition of the Symposium will delve extensively into regulatory aspects related to nasal and pulmonary drug delivery.
Dr. Alan Hendricker, a Principal Scientist for Catalent, will be among the industry experts at the Symposium. He will give a presentation titled “Leachables and Extractables: Regulatory Context.” Dr. Hendricker works on the structural chemistry team within Catalent’s Development and Clinical Services segment, based in North Carolina’s Research Triangle Park. He specializes in gas chromatography mass spectrometry (GC-MS), liquid chromatography mass spectrometry (LC-MS), and headspace analysis for volatile impurities. Dr. Hendricker was a member of the PQRI working group that developed “Safety Threshold and Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products” in 2006. He received his B.S. in Chemistry from Ohio University in Athens, Ohio, and his Ph.D. in Chemistry from the Colorado School of Mines in Golden, Colorado.
Catalent Pharma Solutions provides a broad range of development, clinical, regulatory and supply chain solutions for nasal products, as well as for respiratory products in nebulized, metered dose and dry powder forms. For more information about Catalent’s development and clinical offerings, visit www.catalent.com/development.
About Catalent:
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,500 at 30 facilities worldwide and in fiscal 2008 generated more than $1.8 billion in annual revenue. For more information, visit www.catalent.com
